Prevalence and Severity of Cramps in Chronic Kidney Disease Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
Cramps are a frequent and severe complication in CKD patients. Their characteristics : triggering factors, associated factors, are not well known. There is no recognized effective treatment. Using a questionnaire, the investigators wish to determine prevalence, severity and associated factors of cramps in our CKD patients. Better knowledge about cramps in CKD patients will allow to better support, and give a practical tool for treatment evaluation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Voluntary patients with CKD III to V (GFR<60ml/mn/1,72M2), including dialysed patients (hemodialysis or peritoneal dialysis).
Non opposed to participate to the research.
Disqualifiers
Transplanted patient with functional graft.
Trial population
Every patient with Chronic Kidney Disease (non dialysis and dialysis patients)
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
250 Participants
are grouped into 1 trial groupGroup A: Chronic Kidney Disease (CKD) Patients
Trial outcomes
Primary outcomes
1
Prevalence of cramps in CKD III-V patients. Number of patients having cramps / number of questionned patients
Time frame
Day 0 - visit of inclusionSecondary outcomes
1
Measure of Severity of cramps
with a scale
Time frame
Day 0 - visit of inclusion2
Frequency of pain intensity
Time frame
Day 0 - visit of inclusion3
Identification of potential triggering factors
through a questionnaire triggering factors will be identified
Time frame
Day 0 - visit of inclusion4
Identification of associated factors (ionic desorders, medical treatment, degree of CKD, …)
Time frame
Day 0 - visit of inclusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: